Market Cap 562.61M
Revenue (ttm) 0.00
Net Income (ttm) -29.44M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 2,074,500
Avg Vol 1,544,262
Day's Range N/A - N/A
Shares Out 54.41M
Stochastic %K 77%
Beta 0.09
Analysts Strong Sell
Price Target $20.67

Company Profile

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

Industry: Biotechnology
Sector: Healthcare
Phone: 310 651 8041
Address:
11400 West Olympic Boulevard, Suite 200, Los Angeles, United States
Dingalingading
Dingalingading Jul. 1 at 8:07 PM
0 · Reply
Isitreallyhim
Isitreallyhim Jul. 1 at 1:26 PM
$IMMX This dog is only up 46% in 5 years. Why do you people waste your time on this slop ????
6 · Reply
Ivorthedriver
Ivorthedriver Jul. 1 at 1:26 PM
$IMMX WTF?? This is from ~10 days ago and I just saw it...who are these guys? Refinitiv/Verus downgrades Immix Biopharma from BUY to SELL. Ivor
3 · Reply
frankinsense69
frankinsense69 Jun. 30 at 8:04 PM
$IMMX meh
2 · Reply
Bernic88
Bernic88 Jun. 30 at 5:10 PM
$IMMX the next $ABVX from the perspective of the share price?🤔 I wouldn't mind, but there is still some work to be done
1 · Reply
Laynester
Laynester Jun. 30 at 4:18 PM
$RARE $NESR $IMMX $COGT $BCRX [DASH] [RKT] [BRBR] [INSM] [VKTX] [BBIO] [AG] [HL] [PSLV] Bears, Sell Calls, Buy Puts please document your BEAR CASE: MASSIVE PORTFOLIO BOTTOM UP SCANNER BUYS today: see attached image. All (any) national Patriot un predjudice Men secure your FAMILY, HOME, TOWN, STATE, BORDER and all FUTURE ELECTIONS. All for one! and One for all! Let's Roll! Set a stop. Good to all us "world slaves". All above and below 100% --->🦬
0 · Reply
scooot
scooot Jun. 30 at 2:56 PM
$IMMX Landau's recent commentary on the regulatory pathway leaves some room for ambiguity; it seems like it should be a slam dunk. She implies the FDA may be mandating randomized trials in all AL amyloidosis approvals (hopefully just as confirmatory or 1L setting where this makes more sense). Would be a shame since it's not really ethical given no 2L standard of care. Would be awesome if we can get an eventual PR that FDA has confirmed alignment that NEXICART-2 is in fact sufficient as a registrational trial. My apologies if this has already been discussed; has there been any clear confirmation on this? 🌟🤝🍻
2 · Reply
mikema1
mikema1 Jun. 30 at 2:20 PM
$IMMX 4 million short shares trapped since 6/15.
0 · Reply
NoUsernameLeft
NoUsernameLeft Jun. 30 at 5:30 AM
$IMMX 🌕🌖🌗🌘🌑🌒🌓🌔🌙
0 · Reply
Fosco_
Fosco_ Jun. 29 at 9:39 PM
$IMMX $SLS basically doubled into the mid $15S 👀 The spark? Amended change-of-control severance for 3 execs. The fuel? 33% short float + an imminent REGAL readout. The market did the rest. $IMMX management — the asset already carries the story (Sept NEXICART-2, BLA 1H27, CMC de-risked, in-house manufacturing). A little CIC governance housekeeping costs nothing and signals the board is thinking about optionality. Just saying 😏
1 · Reply
Latest News on IMMX
Immix Biopharma initiated with a Buy at BofA

2026-06-18T10:22:43.000Z - 16 days ago

Immix Biopharma initiated with a Buy at BofA


Immix Biopharma Slides: Corporate presentation

Jun 17, 2026, 7:00 AM EDT - 17 days ago

Immix Biopharma Slides: Corporate presentation


Immix Biopharma Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 2 months ago

Immix Biopharma Quarterly report: Q1 2026


Immix Biopharma Slides: Corporate presentation

Apr 30, 2026, 7:00 AM EDT - 2 months ago

Immix Biopharma Slides: Corporate presentation


Immix Biopharma Proxy statement: Proxy filing

Apr 6, 2026, 8:00 AM EDT - 3 months ago

Immix Biopharma Proxy statement: Proxy filing


Immix Biopharma Proxy statement: Proxy filing

Apr 6, 2026, 8:00 AM EDT - 3 months ago

Immix Biopharma Proxy statement: Proxy filing


Immix Biopharma price target raised to $15 from $14 at Mizuho

2026-03-30T11:30:46.000Z - 3 months ago

Immix Biopharma price target raised to $15 from $14 at Mizuho


Immix Biopharma Annual report: Q4 2025

Mar 25, 2026, 7:00 AM EDT - 3 months ago

Immix Biopharma Annual report: Q4 2025


Immix Biopharma initiated with an Overweight at Morgan Stanley

2026-03-25T08:55:10.000Z - 3 months ago

Immix Biopharma initiated with an Overweight at Morgan Stanley


Immix Biopharma initiated with an Outperform at Citizens

2026-03-09T08:50:20.000Z - 4 months ago

Immix Biopharma initiated with an Outperform at Citizens


Immix Biopharma Slides: Corporate presentation

Mar 4, 2026, 6:00 AM EST - 4 months ago

Immix Biopharma Slides: Corporate presentation


Immix Biopharma to Participate in Upcoming Investor Conferences

Mar 3, 2026, 8:45 AM EST - 4 months ago

Immix Biopharma to Participate in Upcoming Investor Conferences


Immix Biopharma initiated with an Outperform at Mizuho

2026-02-09T10:40:13.000Z - 5 months ago

Immix Biopharma initiated with an Outperform at Mizuho


Immix Biopharma files $750M mixed securities shelf

2026-01-09T22:30:15.000Z - 6 months ago

Immix Biopharma files $750M mixed securities shelf


Immix Biopharma Registration statement: Registration Filing

Jan 9, 2026, 7:00 AM EST - 6 months ago

Immix Biopharma Registration statement: Registration Filing


Immix Biopharma 19.12M share Spot Secondary priced at $5.10

2025-12-08T11:25:27.000Z - 7 months ago

Immix Biopharma 19.12M share Spot Secondary priced at $5.10


Immix Biopharma announces phase 2 NXC-201 results

2025-12-08T01:50:12.000Z - 7 months ago

Immix Biopharma announces phase 2 NXC-201 results


Immix Biopharma appoints Grabow as Chief Commercial Officer

2025-11-12T13:50:43.000Z - 8 months ago

Immix Biopharma appoints Grabow as Chief Commercial Officer


Immix Biopharma Quarterly report: Q3 2025

Nov 7, 2025, 4:00 PM EST - 8 months ago

Immix Biopharma Quarterly report: Q3 2025


Immix Biopharma Registration statement: Registration Filing

Oct 6, 2025, 8:00 AM EDT - 9 months ago

Immix Biopharma Registration statement: Registration Filing


Immix Biopharma appoints Nancy Chang to board of directors

2025-09-11T13:35:30.000Z - 10 months ago

Immix Biopharma appoints Nancy Chang to board of directors


Immix Biopharma Quarterly report: Q2 2025

Aug 8, 2025, 7:00 AM EDT - 11 months ago

Immix Biopharma Quarterly report: Q2 2025


Immix Biopharma Announces Other Serious Diseases Strategy

Aug 6, 2025, 12:30 PM EDT - 11 months ago

Immix Biopharma Announces Other Serious Diseases Strategy


Immix Biopharma Slides: Corporate Presentation

Jun 30, 2025, 7:00 AM EDT - 1 year ago

Immix Biopharma Slides: Corporate Presentation


Immix Biopharma Attends FDA CEO Forum in Washington DC

Jun 6, 2025, 9:39 AM EDT - 1 year ago

Immix Biopharma Attends FDA CEO Forum in Washington DC


Immix Biopharma Transcript: Status Update

Jun 3, 2025, 3:00 PM EDT - 1 year ago

Immix Biopharma Transcript: Status Update


Immix Biopharma Press release: Status Update

Jun 3, 2025, 3:00 PM EDT - 1 year ago

Immix Biopharma Press release: Status Update


Immix Biopharma Proxy statement: Proxy Filing

May 19, 2025, 8:00 AM EDT - 1 year ago

Immix Biopharma Proxy statement: Proxy Filing


Immix Biopharma Quarterly report: Q1 2025

May 7, 2025, 6:00 PM EDT - 1 year ago

Immix Biopharma Quarterly report: Q1 2025


Immix Biopharma Proxy statement: Proxy Filing

May 5, 2025, 8:00 AM EDT - 1 year ago

Immix Biopharma Proxy statement: Proxy Filing


Immix Biopharma Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Immix Biopharma Proxy statement: Proxy Filing


Immix Biopharma Annual report: Q4 2024

Mar 25, 2025, 8:00 AM EDT - 1 year ago

Immix Biopharma Annual report: Q4 2024


Immix Biopharma Slides: Investor Presentation

Jan 20, 2025, 6:00 PM EST - 1 year ago

Immix Biopharma Slides: Investor Presentation


Immix Biopharma Quarterly report: Q3 2024

Nov 11, 2024, 6:00 PM EST - 1 year ago

Immix Biopharma Quarterly report: Q3 2024


Immix Biopharma Quarterly report: Q2 2024

Aug 11, 2024, 6:00 PM EDT - 2 years ago

Immix Biopharma Quarterly report: Q2 2024


Immix Biopharma Proxy statement: Proxy Filing

May 21, 2024, 8:00 AM EDT - 2 years ago

Immix Biopharma Proxy statement: Proxy Filing


Immix Biopharma Quarterly report: Q1 2024

May 8, 2024, 6:00 PM EDT - 2 years ago

Immix Biopharma Quarterly report: Q1 2024


Immix Biopharma Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Immix Biopharma Proxy statement: Proxy Filing


Immix Biopharma Annual report: Q4 2023

Mar 28, 2024, 7:00 PM EDT - 2 years ago

Immix Biopharma Annual report: Q4 2023


Immix Biopharma 12 Month Review Progress Update

Feb 21, 2024, 9:31 AM EST - 2 years ago

Immix Biopharma 12 Month Review Progress Update


Dingalingading
Dingalingading Jul. 1 at 8:07 PM
0 · Reply
Isitreallyhim
Isitreallyhim Jul. 1 at 1:26 PM
$IMMX This dog is only up 46% in 5 years. Why do you people waste your time on this slop ????
6 · Reply
Ivorthedriver
Ivorthedriver Jul. 1 at 1:26 PM
$IMMX WTF?? This is from ~10 days ago and I just saw it...who are these guys? Refinitiv/Verus downgrades Immix Biopharma from BUY to SELL. Ivor
3 · Reply
frankinsense69
frankinsense69 Jun. 30 at 8:04 PM
$IMMX meh
2 · Reply
Bernic88
Bernic88 Jun. 30 at 5:10 PM
$IMMX the next $ABVX from the perspective of the share price?🤔 I wouldn't mind, but there is still some work to be done
1 · Reply
Laynester
Laynester Jun. 30 at 4:18 PM
$RARE $NESR $IMMX $COGT $BCRX [DASH] [RKT] [BRBR] [INSM] [VKTX] [BBIO] [AG] [HL] [PSLV] Bears, Sell Calls, Buy Puts please document your BEAR CASE: MASSIVE PORTFOLIO BOTTOM UP SCANNER BUYS today: see attached image. All (any) national Patriot un predjudice Men secure your FAMILY, HOME, TOWN, STATE, BORDER and all FUTURE ELECTIONS. All for one! and One for all! Let's Roll! Set a stop. Good to all us "world slaves". All above and below 100% --->🦬
0 · Reply
scooot
scooot Jun. 30 at 2:56 PM
$IMMX Landau's recent commentary on the regulatory pathway leaves some room for ambiguity; it seems like it should be a slam dunk. She implies the FDA may be mandating randomized trials in all AL amyloidosis approvals (hopefully just as confirmatory or 1L setting where this makes more sense). Would be a shame since it's not really ethical given no 2L standard of care. Would be awesome if we can get an eventual PR that FDA has confirmed alignment that NEXICART-2 is in fact sufficient as a registrational trial. My apologies if this has already been discussed; has there been any clear confirmation on this? 🌟🤝🍻
2 · Reply
mikema1
mikema1 Jun. 30 at 2:20 PM
$IMMX 4 million short shares trapped since 6/15.
0 · Reply
NoUsernameLeft
NoUsernameLeft Jun. 30 at 5:30 AM
$IMMX 🌕🌖🌗🌘🌑🌒🌓🌔🌙
0 · Reply
Fosco_
Fosco_ Jun. 29 at 9:39 PM
$IMMX $SLS basically doubled into the mid $15S 👀 The spark? Amended change-of-control severance for 3 execs. The fuel? 33% short float + an imminent REGAL readout. The market did the rest. $IMMX management — the asset already carries the story (Sept NEXICART-2, BLA 1H27, CMC de-risked, in-house manufacturing). A little CIC governance housekeeping costs nothing and signals the board is thinking about optionality. Just saying 😏
1 · Reply
Daddy044
Daddy044 Jun. 29 at 8:07 PM
$IMMX let’s see what happens tmrw. Strong day
1 · Reply
frankinsense69
frankinsense69 Jun. 29 at 7:31 PM
$IMMX New all time high incoming in the next week
0 · Reply
Fosco_
Fosco_ Jun. 29 at 9:07 AM
$IMMX NXC-201 thesis keeps tightening : - Landau's latest: standing 95% CR (19/20 mature), pathologic light chains normalizing by a med of 7 days, low-grade CRS reversed with toci, zero neurotoxicity including delayed. Trial now complete at 42 pts, no dose-limiting tox. She flags the usual worry that regulators lean toward randomized trials, but RMAT + BTD formally open the accelerated path, the 95% magnitude carries the persuasiveness, and 1-yr durability backs the surrogate IMO. - CMC is the quiet topic nobody discussed. However: 14-day vein-to-vein in 100% of pts (industry runs 30+), and a full-time CMC lead, Davis-Pickett, ex-Juno/Breyanzi, who carried Module 3 through to BLA. - Plenty of cash, dilution digested. Sept 2026 update, then 1-yr data circa Mar 2027 drives the BLA. Watching the pre-BLA meeting (Q4 '26?). Also watching $REPL Aug 2 PDUFA — first real test of FDA's appetite for single-arm data post its June draft guidance. IMMX data is cleaner than REPL btw.
4 · Reply
Ivorthedriver
Ivorthedriver Jun. 27 at 3:22 PM
$IMMX WHY WE INVEST! If you haven't read this yet I suggest you do. Boogaloo has shared a wonderful, plain language find of his from Heather Landau. It ain't long and for people like me who don't know an antibody from an antigen it's a fairly easy read that can help you explain to your relatives why you have so much $$ invested here. READ IT!! IVOR P.S. Thanks again for sharing it Boogie.
0 · Reply
bnglao24
bnglao24 Jun. 27 at 11:16 AM
$IMMX https://x.com/Abdallah81MD/status/2070759095276060855?s=20 Who is this guy and what is he talking about?
2 · Reply
Daddy044
Daddy044 Jun. 26 at 10:11 PM
$IMMX New highs coming next week
2 · Reply
mikema1
mikema1 Jun. 26 at 8:57 PM
$IMMX 4 million shares block at close. Index funds has bought 9 million shares.
0 · Reply
frankinsense69
frankinsense69 Jun. 26 at 8:17 PM
$IMMX Two major passive investing milestones now confirmed: 1️⃣ Russell 3000 – Officially added effective today. The closing cross included 4,164,290 shares at $9.98, illustrating the enormous index-rebalancing activity at the close. 2️⃣ XBI – Now confirmed as a holding with 2,097,811 IMMX shares, representing approximately 0.199% of the ETF. Together, these additions mean millions of IMMX shares are now held by passive/index investors, increasing institutional ownership, improving liquidity, and reducing the actively traded float. The index rebalancing is now behind us. From here, the stock trades on fundamentals: BCMA CAR-T progress, regulatory milestones, analyst coverage, and any strategic partnership or M&A developments. Excited for what’s next.
1 · Reply
frankinsense69
frankinsense69 Jun. 26 at 8:01 PM
$IMMX solid close
0 · Reply
frankinsense69
frankinsense69 Jun. 26 at 7:36 PM
$IMMX Should “barcode” rest of day Then expect 6M shares at close and shortly thereafter
0 · Reply
bnglao24
bnglao24 Jun. 26 at 7:21 PM
$IMMX https://www.targetedonc.com/view/deep-responses-support-push-for-car-t-cell-therapy-in-al-amyloidosis “What was really impressive and different was what we saw was the patients who were sickest coming into the trial, who had high light chains or obvious organ progression due to their relapsing disease, experienced significant clinical benefit very rapidly—as soon as the light chains were controlled. I can’t say I’ve witnessed that with any other therapy that I’ve given.” Last sentence. She’s participating in abbvies (etentamig) study as well. I’ll take clinical benefit as the differentiator any day. If immix is collecting quality of life data, this is a big deal
1 · Reply
frankinsense69
frankinsense69 Jun. 26 at 4:17 PM
$IMMX Short Interest update Slight decrease
1 · Reply